8-K: Aethlon Medical Receives Key Ethics Approval for Hemopurifier Cancer Trial

Aethlon Medical has secured a second ethics committee approval to proceed with a clinical trial of its Hemopurifier device in cancer patients at Pindara Private Hospital in Australia.

Summary

• Aethlon Medical has received full ethics approval from the Bellberry Human Research Ethics Committee (BHREC) for a clinical trial at Pindara Private Hospital in Australia.
• The trial will assess the safety, feasibility, and optimal dosage of the Hemopurifier in patients with solid tumors who have not responded to anti-PD-1 antibody treatments.
• This is the second ethics approval Aethlon has received for this oncology trial in Australia, with the first being from the Royal Adelaide Hospital in June.
• The trial will involve approximately 9 to 18 patients and will monitor adverse events and changes in lab tests after a two-month run-in period of anti-PD-1 therapy.
• Patients will receive 1, 2, or 3 Hemopurifier treatments over a week, and the study will also examine the impact on extracellular vesicle (EV) concentrations and the body's ability to fight tumors.
• The Hemopurifier is designed to remove EVs from the bloodstream, which may improve the effectiveness of anti-PD-1 therapies.
• The approval is valid for one year, until August 6, 2025.

Sentiment

Score: 7

Explanation: The document is positive due to the ethics approval and progress in clinical trials, but it also acknowledges the risks and uncertainties associated with the development of the Hemopurifier. The sentiment is cautiously optimistic.

Positives

• The second ethics approval for the Hemopurifier trial in Australia indicates progress in clinical development.
• The trial will assess the safety and feasibility of the Hemopurifier in a patient population with unmet medical needs.
• The Hemopurifier has shown potential in preclinical studies to reduce exosomes in cancer patient plasma samples.
• The study will explore the impact of Hemopurifier treatments on EV concentrations and the body's ability to attack tumor cells.
• The trial is designed to inform the design of a subsequent efficacy and safety study required by regulatory agencies.

Negatives

• The trial is still in the early stages, focusing on safety, feasibility, and dose-finding.
• The trial involves a small number of patients (approximately 9 to 18), which may limit the generalizability of the results.
• The study is dependent on further approvals from Research Governance Offices at each hospital.

Risks

• The company's ability to successfully complete the development of the Hemopurifier and demonstrate its safety and utility in patients is not guaranteed.
• The company's ability to obtain approvals from Research Governance Offices at relevant hospitals and complete site initiation visits in a timely manner is not guaranteed.
• The company's ability to recruit patients for and manage its clinical trials and studies is subject to various factors.
• Unforeseen changes in regulatory requirements could impact the trial and the development of the Hemopurifier.

Future Outlook

The company plans to obtain approvals from Research Governance Offices at each hospital, conduct Site Initiation Visits (SIVs), and then proceed with patient enrollment. The results of this trial are expected to inform the design of a subsequent efficacy and safety study required by regulatory agencies.

Management Comments

• Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical, stated that the BHREC accepted their responses to their questions and determined that the study meets the requirements of the National Statement application.
• Dr. LaRosa also noted that Dr. Matos and his research team have a proven track record of enrollment in device trials in oncology patients.

Industry Context

The announcement is relevant to the oncology field, particularly in the area of immunotherapy resistance. The Hemopurifier's approach to removing extracellular vesicles (EVs) is a novel strategy to potentially improve the effectiveness of anti-PD-1 therapies, which are widely used but often face resistance issues. This could position Aethlon as a player in the development of combination therapies to overcome this resistance.

Comparison to Industry Standards

• The trial design, focusing on safety, feasibility, and dose-finding, is standard for early-stage clinical trials of medical devices.
• The use of anti-PD-1 therapies like Keytruda and Opdivo as a baseline for comparison is common in oncology trials.
• The focus on extracellular vesicles (EVs) aligns with current research trends in cancer biology and drug resistance.
• Comparable companies in the medical device space, such as those developing novel cancer therapies, often follow a similar phased approach to clinical trials, starting with safety and feasibility studies before moving to larger efficacy trials.

Stakeholder Impact

• Shareholders may view the ethics approval as a positive step in the development of the Hemopurifier.
• Patients with solid tumors who have not responded to anti-PD-1 therapies may benefit from the potential of the Hemopurifier.
• Employees of Aethlon Medical are likely to be impacted by the progress of the clinical trial.
• The company's suppliers and partners may be impacted by the progress of the clinical trial.

Next Steps

• The company will seek approvals from the Research Governance Offices at each hospital.
• Site Initiation Visits (SIVs) will be conducted in collaboration with the Australian Contract Research Organization, ReSQ.
• Patient enrollment will commence after the necessary approvals and SIVs are completed.

Key Dates

Keywords

Hemopurifier, Cancer, Clinical Trial, Ethics Approval, Solid Tumors, Anti-PD-1 Antibodies, Extracellular Vesicles, Oncology, Aethlon Medical, Pindara Private Hospital